サマリー

中東・アフリカの水頭症市場は、2023年の53,050,71千米ドルから2031年には73,700,58千米ドルに達すると予測され、2024年から2031年の予測期間において年平均成長率4.4%で成長すると予測される。
市場区分
中東・アフリカ水頭症市場：タイプ別（先天性水頭症、後天性水頭症、正常圧水頭症、外水頭症）、診断・治療別（診断と治療）、エンドユーザー別（病院、診療所、診断センター、学術機関・研究機関）、国別（サウジアラビア、南アフリカ、U.A.E.、イスラエル、エジプト、中東・アフリカその他）-産業動向と2031年までの予測
中東およびアフリカの水頭症市場ダイナミクスの概要

促進要因
- 神経疾患の発生率の増加
抑制要因

- 不十分な償還政策

機会

- 医療機関や政府機関による支援の拡大

市場プレイヤー

中東・アフリカの水頭症市場で事業を展開する主な市場参入企業は以下の通り：

- B. Braun傘下のAesculap, Inc.
- インテグラ・ライフサイエンス
- ジー・サーギウェア社
- モレール・メディカル社
- アヌンシア社
- クリストフ・ミースケGmbH & co.KG
- KARL STORZ SE & Co.KG
- 株式会社プロテテス
- メドトロニック
- ナタス
- デスーメディカル
- ビカクシラー
- シュピーゲルベルグGmbH & Co.KG
- ソフィサ
- カネカメディックス

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET 18
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 19
2 MARKET SEGMENTATION 22
2.1 MARKETS COVERED 22
2.2 GEOGRAPHICAL SCOPE 23
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 CURRENCY AND PRICING 24
2.5 DBMR TRIPOD DATA VALIDATION MODEL 25
2.6 MULTIVARIATE MODELLING 28
2.7 TYPE LIFELINE CURVE 28
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.9 DBMR MARKET POSITION GRID 30
2.10 VENDOR SHARE ANALYSIS 31
2.11 SECONDARY SOURCES 32
2.12 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 35
5 MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET: REGULATIONS 36
5.1 REGULATIONS IN U.S. 36
5.2 REGULATIONS IN EUROPE 36
5.3 REGULATIONS IN INDIA 36
5.4 REGULATIONS IN JAPAN 37
5.5 REGULATIONS IN BRAZIL 37
6 MARKET OVERVIEW 38
6.1 DRIVERS 40
6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 40
6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 40
6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 41
6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 41
 
6.2 RESTRAINTS 42
6.2.1 POOR REIMBURSEMENT POLICIES 42
6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 42
6.3 OPPORTUNITIES 43
6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 43
6.3.2 GROWING HEALTHCARE EXPENDITURE 44
6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 44
6.4 CHALLENGES 45
6.4.1 HIGH PRODUCT RECALL SCENARIO 45
6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 45
7 MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET, BY TYPE 46
7.1 OVERVIEW 47
7.2 CONGENITAL HYDROCEPHALUS 50
7.3 ACQUIRED HYDROCEPHALUS 50
7.4 NORMAL-PRESSURE HYDROCEPHALUS 51
7.5 EX-VACUO HYDROCEPHALUS 51
8 MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 52
8.1 OVERVIEW 53
8.2 DIAGNOSTICS 56
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 56
8.2.2 CT SCAN – HEAD 56
8.2.3 HEAD ULTRASOUND 57
8.3 TREATMENT 57
8.3.1 SURGERY – SHUNT INSERTION, BY PRODUCT TYPE 58
8.3.1.1 HYDROCEPHALUS VALVES 58
8.3.1.2 HYDROCEPHALUS CATHETERS 58
8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 58
8.3.1.2.2 FIX PRESSURE VALVES 59
8.3.2 SURGERY – SHUNT INSERTION, BY AGE GROUP 59
8.3.2.1 PEDIATRIC 59
8.3.2.2 ADULT 59
8.3.3 VENTRICULOSTOMY 59
8.3.4 MEDICATION 59
8.3.5 TREATMENT, BY AGE GROUP 60
8.3.6 INFANTS 60
8.3.7 CHILDREN 60
8.3.8 ADULTS 60
9 MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET, BY END USERS 61
9.1 OVERVIEW 62
9.2 HOSPITALS 65
9.3 CLINICS 65
9.4 DIAGNOSTIC CENTERS 66
9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 66
9.5.1 HOSPITALS 67
9.5.2 AMBULATORY AND SURGICAL CENTERS 67
9.5.3 HOSPITALS 67
9.5.4 CLINICS 67
9.5.5 DIAGNOSTIC CENTER 68
9.5.6 SURGICAL CENTERS 68
9.5.7 AMBULATORY SURGICAL CENTERS 68
9.5.8 OTHERS 68
10 MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET, BY REGION 69
10.1 ASIA-PACIFIC 71
10.1.1 JAPAN 76
10.1.2 CHINA 80
10.1.3 SOUTH KOREA 84
10.1.4 INDIA 88
10.1.5 AUSTRALIA 92
10.1.6 SINGAPORE 96
10.1.7 THAILAND 100
10.1.8 MALAYSIA 104
10.1.9 INDONESIA 108
10.1.10 PHILIPPINES 112
10.1.11 VIETNAM 116
10.1.12 REST OF ASIA-PACIFIC 120
11 MIDDLE EAST AND AFRICA HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 121
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 121
12 SWOT ANALYSIS 122
13 COMPANY PROFILE 123
13.1 MEDTRONIC 123
13.1.1 COMPANY SNAPSHOT 123
13.1.2 REVENUE ANALYSIS 123
13.1.3 COMPANY SHARE ANALYSIS 124
13.1.4 PRODUCT PORTFOLIO 124
13.1.5 RECENT DEVELOPMENTS 124
13.2 AESCULAP, INC. – A B. BRAUN COMPANY 125
13.2.1 COMPANY SNAPSHOT 125
13.2.2 COMPANY SHARE ANALYSIS 125
13.2.3 PRODUCT PORTFOLIO 126
13.2.4 RECENT DEVELOPMENT 126
13.3 INTEGRA LIFESCIENCES 127
13.3.1 COMPANY SNAPSHOT 127
13.3.2 REVENUE ANALYSIS 127
13.3.3 COMPANY SHARE ANALYSIS 128
13.3.4 PRODUCT PORTFOLIO 128
13.3.5 RECENT DEVELOPMENT 129
13.4 SPIEGELBERG GMBH & CO. KG 130
13.4.1 COMPANY SNAPSHOT 130
13.4.2 COMPANY SHARE ANALYSIS 130
13.4.3 PRODUCT PORTFOLIO 131
13.4.4 RECENT DEVELOPMENT 131
13.5 BICAKCILAR 132
13.5.1 COMPANY SNAPSHOT 132
13.5.2 COMPANY SHARE ANALYSIS 132
13.5.3 PRODUCT PORTFOLIO 133
13.5.4 RECENT DEVELOPMENTS 133
13.6 ANUNCIA INC 134
13.6.1 COMPANY SNAPSHOT 134
13.6.2 PRODUCT PORTFOLIO 134
13.6.3 RECENT DEVELOPMENT 134
13.7 CHRISTOPH MIETHKE GMBH & CO. KG 135
13.7.1 COMPANY SNAPSHOT 135
13.7.2 PRODUCT PORTFOLIO 135
13.7.3 RECENT DEVELOPMENT 136
13.8 DESU MEDICAL 137
13.8.1 COMPANY SNAPSHOT 137
13.8.2 PRODUCT PORTFOLIO 137
13.8.3 RECENT DEVELOPMENT 137
13.9 G.SURGIWEAR LTD 138
13.9.1 COMPANY SNAPSHOT 138
13.9.2 PRODUCT PORTFOLIO 138
13.9.3 RECENT DEVELOPMENT 138
 
13.10 HPBIO 139
13.10.1 COMPANY SNAPSHOT 139
13.10.2 PRODUCT PORTFOLIO 139
13.10.3 RECENT DEVELOPMENT 139
13.11 KANEKA MEDIX CORP 140
13.11.1 COMPANY SNAPSHOT 140
13.11.2 REVENUE ANALYSIS 140
13.11.3 PRODUCT PORTFOLIO 142
13.11.4 RECENT DEVELOPMENTS 142
13.12 KARL STORZ SE & CO. KG 143
13.12.1 COMPANY SNAPSHOT 143
13.12.2 PRODUCT PORTFOLIO 143
13.12.3 RECENT DEVELOPMENT 143
13.13 MÖLLER MEDICAL GMBH 144
13.13.1 COMPANY SNAPSHOT 144
13.13.2 PRODUCT PORTFOLIO 144
13.13.3 RECENT DEVELOPMENT 144
13.14 NATUS MEDICAL INCORPORATED 145
13.14.1 COMPANY SNAPSHOT 145
13.14.2 PRODUCT PORTFOLIO 145
13.14.3 RECENT DEVELOPMENTS 146
13.15 SOPHYSA 147
13.15.1 COMPANY SNAPSHOT 147
13.15.2 PRODUCT PORTFOLIO 147
13.15.3 RECENT DEVELOPMENTS 148
14 QUESTIONNAIRE 149
15 RELATED REPORTS 152